HOME >> BIOLOGY >> NEWS
Telling axons where to go and grow

In a recent study, Dr. Ingolf Bach and colleagues from the University of Massachusetts Medical School, Worcester and the University of Hamburg (Germany) describe a novel role for the ubiquitin/proteosome protein degradation pathway in the regulation of local actin dynamics in neurons.

The authors are able to show that the ubiquitin ligase Rnf6 polyubiquitinates the kinase LIMK1, targeting it for proteosomal degradation in the growth cones of hippocampal neurons. LIMK1 regulates the dynamics of the actin cytoskeleton primarily via phosphorylation of the actin depolymerization factors ADF/cofilin, with important consequences for cell morphology, cell motility, and the development of neuronal projections. Changes in LIMK1 concentration have an impact in neuronal growth cone actin dynamics and axon formation.

The authors focus on the RING finger protein Rnf6 due to its similarity to the previously identified protein RLIM, which has been shown to bind to nuclear LIM domains and critically regulate the biological activity of LIM-HD transcription factors. The authors find high levels of Rnf6 protein in axonal projections of motor neurons and dorsal root ganglia neurons in mouse embryos at a time in which projections are actively developing, suggesting a role of this protein in the development of these neurons. They are able to show that this is indeed the case by RNAi-mediated knock-down of Rnf6 in primary hippocampal neurons, which stimulate axon outgrowth, and by over-expression of Rnf6 that results in a significant decrease in axon length.

Finding that Rnf6 targets LIMK1 for degradation finally closes this circle of regulation, providing the link between actin dynamics, axonal growth and Rnf6. Importantly, the authors are able to show that changes in axon outgrowth induced by changes in levels of Rnf6 can be restored by compensatory changes in LIMK1 expression, thereby giving Rnf6 a central role in controlling actin dynamics in subcellul
'"/>

Contact: Heather Cosel
coselpie@cshl.edu
Cold Spring Harbor Laboratory
30-Sep-2005


Page: 1 2

Related biology news :

1. Telling the likes apart
2. Potent anticancer drug increases function of axons in mouse model of neurodegeneration
3. High-intensity ultrasound may launch attack on cancer, wherever it lurks
4. Waters off Washington state only second place in world where glass sponge reefs found
5. Fruit fly gene from out of nowhere is discovered
6. Where did we come from, and how did we get to where we live today?
7. Why do oysters choose to live where they could be eaten?
8. Unraveling where chimp and human brains diverge
9. Plant studies reveal how, where seeds store iron
10. Unique imaging uncovers the invisible world where surfaces meet
11. Hermaphroditic plants have genetic advantage in areas where extinctions are frequent

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Telling axons where and grow

(Date:5/21/2013)... largest gathering of biomass experts , Where? ... When? 03-07 June 2013 , ... research, resource assessment, market and policy developments, manufacturing and ... world and benefiting from its 2013 edition from a ... than 60 countries, more than 240 plenary and oral ...
(Date:5/21/2013)... epigenetic modifications, which alter the way genes function ... be detected in the blood of pregnant women ... to foretell depression in the weeks after giving ... become debilitating. , The findings of the small ... in the journal Molecular Psychiatry . , ...
(Date:5/20/2013)... the effect of physical education (PE) on child weight, ... increasing the amount of time that elementary schoolchildren spent ... The study represents some of the first evidence of ... is forthcoming in the Journal of Health Economics ... can be viewed at: http://www.sciencedirect.com/science/article/pii/S0167629613000556 , The ...
Breaking Biology News(10 mins):21st European Biomass Conference and Exhibition 221st European Biomass Conference and Exhibition 321st European Biomass Conference and Exhibition 4Genetic predictors of postpartum depression uncovered by Hopkins researchers 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 3Gym class reduces probability of obesity, study finds for first time 2
(Date:5/21/2013)... Wisc. (PRWEB) May 21, 2013 ... parts distributor , will be exhibiting for the ... Advancement of Medical Instrumentation (AAMI) 2013 Conference and ... purchase, support, distribute, and manufacture healthcare technologies. This ... in Long Beach, California. , The three-day ...
(Date:5/21/2013)... NC (PRWEB) May 21, 2013 ... financial services company for clinical trials, announced today ... Spend Solutions, LLC. Clinverse’s ClinPay® FLS eClinical ... investigator payment process. SpendMD ™, Aggregate ... complete solution for tracking and reporting transfer of ...
(Date:5/21/2013)... Canada (PRWEB) May 21, 2013 ... is a strong push within the industry to ... and Manufacturing Organizations and pharma companies often means ... frames. , Microtablets, developed in collaboration with Sensidose ... effective outsourcing can bring products to market sooner. ...
(Date:5/21/2013)... , May 21, 2013  MacroGenics, Inc. today ... of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody ... the HER2 oncoprotein," will be presented at the ... Clinical Oncology during the Developmental Therapeutics - Immunotherapy ... 4:15 – 4:30 PM.  The presentation will describe ...
Breaking Biology Technology:Alpha Source, Inc. to Exhibit at the AAMI 2013 Conference and Expo 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
Cached News: